MDM2, MDMX and p53 in oncogenesis and cancer therapy
The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many
human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour
suppressor. However, the MDM proteins modulate and respond to many other signalling
networks in which they are embedded. Recent mechanistic studies and animal models have
demonstrated how functional interactions in these networks are crucial for maintaining
normal tissue homeostasis, and for determining responses to oncogenic and therapeutic …
human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour
suppressor. However, the MDM proteins modulate and respond to many other signalling
networks in which they are embedded. Recent mechanistic studies and animal models have
demonstrated how functional interactions in these networks are crucial for maintaining
normal tissue homeostasis, and for determining responses to oncogenic and therapeutic …
Abstract
The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor. However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded. Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for determining responses to oncogenic and therapeutic challenges. This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.
nature.com